|
Gene: IGDCC3 |
Gene summary for IGDCC3 |
Gene summary. |
Gene information | Species | Human | Gene symbol | IGDCC3 | Gene ID | 9543 |
Gene name | immunoglobulin superfamily DCC subclass member 3 | |
Gene Alias | HsT18880 | |
Cytomap | 15q22.31 | |
Gene Type | protein-coding | GO ID | GO:0003008 | UniProtAcc | Q8IVU1 |
Top |
Malignant transformation analysis |
Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
Malignant transformation involving gene list. |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
9543 | IGDCC3 | S014 | Human | Liver | HCC | 1.71e-30 | 9.85e-01 | 0.2254 |
9543 | IGDCC3 | S015 | Human | Liver | HCC | 2.93e-30 | 1.29e+00 | 0.2375 |
9543 | IGDCC3 | S016 | Human | Liver | HCC | 7.17e-34 | 9.53e-01 | 0.2243 |
Page: 1 |
Transcriptomic changes along malignancy continuum. |
Tissue | Expression Dynamics | Abbreviation |
Liver | HCC: Hepatocellular carcinoma | |
NAFLD: Non-alcoholic fatty liver disease |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
Figure of enriched GO biological processes. |
Tissue | Disease Stage | Enriched GO biological Processes |
Breast | Precancer | |
Breast | IDC | |
Breast | DCIS | |
Cervix | CC | |
Cervix | HSIL_HPV |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
Enriched GO biological processes. |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
Page: 1 |
Enriched KEGG pathways. |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
Annotation of somatic variants for genes involved in malignant transformation |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
IGDCC3 | SNV | Missense_Mutation | c.665G>A | p.Gly222Glu | p.G222E | Q8IVU1 | protein_coding | tolerated(1) | benign(0.017) | TCGA-A1-A0SO-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | SD | ||
IGDCC3 | SNV | Missense_Mutation | novel | c.2152G>C | p.Glu718Gln | p.E718Q | Q8IVU1 | protein_coding | deleterious_low_confidence(0) | probably_damaging(0.996) | TCGA-AC-A5XS-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | femara | SD |
IGDCC3 | SNV | Missense_Mutation | novel | c.269N>G | p.Leu90Trp | p.L90W | Q8IVU1 | protein_coding | deleterious(0) | possibly_damaging(0.907) | TCGA-AN-A0AT-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
IGDCC3 | SNV | Missense_Mutation | c.1763N>T | p.Ala588Val | p.A588V | Q8IVU1 | protein_coding | tolerated(0.4) | benign(0.015) | TCGA-AR-A24K-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unspecific | Paclitaxel | SD | |
IGDCC3 | SNV | Missense_Mutation | c.2296G>A | p.Glu766Lys | p.E766K | Q8IVU1 | protein_coding | deleterious_low_confidence(0.01) | benign(0) | TCGA-BH-A0DH-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cyclophosphamide | SD | |
IGDCC3 | SNV | Missense_Mutation | c.550N>C | p.Glu184Gln | p.E184Q | Q8IVU1 | protein_coding | tolerated(0.11) | possibly_damaging(0.735) | TCGA-E2-A159-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cyclophosphamide | SD | |
IGDCC3 | insertion | Frame_Shift_Ins | novel | c.2257_2258insTGGAG | p.Pro753LeufsTer9 | p.P753Lfs*9 | Q8IVU1 | protein_coding | TCGA-AR-A0TY-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unspecific | Paclitaxel | PD | ||
IGDCC3 | insertion | Frame_Shift_Ins | novel | c.2255_2256insACTCTGTTGCCAAG | p.Pro753LeufsTer12 | p.P753Lfs*12 | Q8IVU1 | protein_coding | TCGA-AR-A0TY-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unspecific | Paclitaxel | PD | ||
IGDCC3 | insertion | In_Frame_Ins | novel | c.1716_1717insGTCTGGAGTCCTGTAGGCAAAGTCAAAGGATGTTCCCACTCC | p.Leu572_Pro573insValTrpSerProValGlyLysValLysGlyCysSerHisSer | p.L572_P573insVWSPVGKVKGCSHS | Q8IVU1 | protein_coding | TCGA-B6-A0IM-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | ||
IGDCC3 | deletion | Frame_Shift_Del | novel | c.1121delN | p.Gly374AlafsTer12 | p.G374Afs*12 | Q8IVU1 | protein_coding | TCGA-D8-A27V-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | tamoxiphen | SD |
Page: 1 2 3 4 5 6 7 8 9 |
Top |
Related drugs of malignant transformation related genes |
Identification of chemicals and drugs interact with genes involved in malignant transfromation |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |